A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group Evaluation of the Efficacy and Safety of 50 mg, 100 mg and 200 mg PP4001 Twice Daily for the Treatment of Burning During Urination, Pain, and Urination Frequency Associated With Uncomplicated Urinary Tract Infection.
Phase of Trial: Phase II
Latest Information Update: 18 Oct 2011
At a glance
- Drugs PP 4001 (Primary)
- Indications Lower urinary tract symptoms
- Focus Therapeutic Use
- 18 Oct 2011 Actual end date (Oct 2011) added as reported by ClinicalTrials.gov.
- 18 Oct 2011 Last checked against ClinicalTrials.gov record.
- 18 Oct 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.